A New Method of Hit Discovery

DNA-Encoded Library (DEL) technology involves a novel affinity selection process that integrates chemistry, biology, bioinformatics and computational chemistry to facilitate a rapid drug discovery process, allowing access to more chemical space with lower cost.



In contrast to high throughput screening, DEL requires a very small amount of target protein and minimum assay development. More importantly, it disrupts the concept of “cost-per-well” and allows testing billions of compounds in one tube.

About DELpro

One-stop solution

Experimental design is set up based on clients’ specific screening needs. Hit series are selected and prioritized through transparent communication and decision-making.

Target exclusivity

IP protection for clients’ target and affinity results.

DELpro

46B+ compounds

There are 6,000+ self-designed scaffolds available in DELpro. Over 150 libraries cover large chemical space and good diversity.

Fast turn-around

Allowing for faster turn-around time than traditional technology.

DELpro provides a one-stop solution from target to hit series. Our extended platform enables overall planning and management of protein production, DEL library production, affinity selection, data analysis, hit validation and structural biology for further optimization.



About WuXi AppTec HitS

WuXi AppTec HitS unit provides a one-stop Target-to-Hit services that enable companies in the pharmaceuticals, biotech and academics worldwide to seek premium drug discovery. As an innovation-driven and customer-focused unit, WuXi AppTec HitS helps our partners improve the productivity of advancing hit discovery through high-quality and cost-effective solutions.



With industry-leading capabilities such as protein science, biophysics, DNA-encoded library technology, and structural biology, WuXi AppTec HitS is committed to drive toward the realization of the vision that every drug can be made and every disease can be treated.

DELpro

One-stop solution, customizable

46+ Billion

Target exclusivity
For all drug developers
Access to unique scaffolds

DELight

Unprecedented data release

15.1 Billion

Target confidentiality
For all drug developers
Easy access with reduced risk

DELopen

Free access to DEL, data sharing

4.4 Billion

Target confidentiality
For academic users
Open source

HitS Website: https://hits.wuxiapptec.com
Contact Us: DEL_service@wuxiapptec.com
North America: Declan Ryan declan.ryan@wuxiapptec.com
Europe: Dave Madge dave_madge@wuxiapptec.com

Our Vision

Every drug can be made and every disease can be treated